Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;21(24):3091-3101.
doi: 10.1080/14796694.2025.2555168. Epub 2025 Oct 7.

Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial

Sherene Loi  1   2 , Roberto Salgado  1   3 , Giuseppe Curigliano  4   5 , Roberto Iván Romero Díaz  6 , Suzette Delaloge  7 , Carlos Ignacio Rojas García  8 , Marleen Kok  9 , Cristina Saura  10 , Nadia Harbeck  11 , Elizabeth A Mittendorf  12 , Denise A Yardley  13 , Alberto Suárez Zaizar  14 , Facundo Rufino Caminos  15 , Andrei Ungureanu  16 , Joaquin G Reinoso-Toledo  17 , Valentina Guarneri  18   19 , Daniel Egle  20   21 , Felipe Ades  22 , Misena Pacius  22 , Aparna Chhibber  22 , Rajalakshmi Chandra  22 , Raheel Nathani  22 , Thomas Spires  22 , Jenny Qun Wu  22 , Lajos Pusztai  23 , Heather McArthur  24
Affiliations

Plain language summary of publication: Comparing nivolumab and neoadjuvant chemotherapy with placebo and neoadjuvant chemotherapy in participants with newly diagnosed estrogen receptor-positive breast cancer in the CheckMate 7FL clinical trial

Sherene Loi et al. Future Oncol. 2025 Oct.
No abstract available

Plain language summary

What is this summary about?What is this summary about?This is a summary of a research article published in the scientific journal Nature Medicine. The article is on the CheckMate 7FL study that compared nivolumab + neoadjuvant chemotherapy with placebo + neoadjuvant chemotherapy in patients with newly diagnosed, high-risk ER+/HER2−breast cancer.In this study, 521 participants who had a complete clearance, also known as a pCR, of their cancer after treatment with nivolumab (an anti-cancer medication) and neoadjuvant chemotherapy were compared with those who received a placebo and neoadjuvant chemotherapy. The researchers also assessed the side effects of treatment with nivolumab or placebo in combination with neoadjuvant chemotherapy.They tried to identify specific groups of participants most likely to respond to and benefit from nivolumab and neoadjuvant chemotherapy by using a set of biological markers, also known as biomarker assessments.What were the results?The results from the study suggest that adding nivolumab to neoadjuvant chemotherapy can significantly increase pCR rates in patients with high-risk ER+/HER2− breast cancer.What do the results mean?Biomarkers are measurable indicators, such as specific cells, proteins, or other markers, that can provide information on how the body responds to treatment. New biomarkers can help identify the most suitable treatment for patients who are more likely to benefit from it.[Box: see text].

PubMed Disclaimer

LinkOut - more resources